Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation

Pharmacogenomics Journal

Volumn 8, Issue 4, 2008, Pages 248-255

  Woodahl, E L ^a,b   Hingorani, S R ^b,c   Wang, J ^a,b   Guthrie, K A ^b   McDonald, G B ^a,b   Batchelder, A ^b   Li, M ^a   Schoch, H G ^b   McCune, J S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 3A5; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BC3; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; TACROLIMUS;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG DISPOSITION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION;

ACUTE DISEASE; COHORT STUDIES; CYTOCHROME P-450 CYP3A; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; MYELOABLATIVE AGONISTS; P-GLYCOPROTEIN; RETROSPECTIVE STUDIES;

EID: 47849103040     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500472     Document Type: Article

References (38)

1. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
2. Hingorani SR, Guthrie K, Batchelder A, Schoch G, Aboulhosn N, Manchion J et al. Acute renal failure after myeloablative hematopoietic cell transplant: Incidence and risk factors. Kidney Int 2005; 67: 272-277.
3. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: Epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 2006; 17: 1995-2005.
4. Hows JM, Palmer S, Gordon-Smith EC. Use of cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anemia. Transplantation 1982; 33: 382-386.
5. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-847.
6. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 2004; 68: 1889-1902.
7. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080.
8. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
9. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004; 5: 11-19.
10. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 2004; 310: 1199-1207.
11. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. Aids 2005; 19: 1617-1625.
12. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584-594.
13. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70 189-199.
14. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-494.
15. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
17. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG et al CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297-1300.
18. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmocol 1996; 50: 52-59.
19. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108-1114.
20. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-172.
21. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-170.
22. Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund S et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmaco-genomics J 2007; 7: 56-65.
23. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-1854.
24. Uwai Y, Masuda S, Goto M, Motohashi H, Saito H, Okuda M et al. Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J Hum Genet 2004; 49: 40-45.
25. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
26. Burckart GJ, Liu XI. Pharmacogenetics in transplant patients: Can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 2006; 28: 23-30.
27. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26: 180-185.
28. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661-674.
29. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-1511.
30. Hingorani SR, Peterson D, Schoch G, Chien JW, Hansen JA, McDonald GB. Genetic polymorphisms associated with acute kidney injury after hematopoietic cell transplant (HCT). J Am Soc Nephrol 2006; 17 405A.
31. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986; 73: 320-326.
32. Chien JW, Zhao LP, Hansen JA, Fan WH, Parimon T, Clark JG. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006; 107: 2200-2207.
33. Saito K, Miyake S, Moriya H, Yamazaki M, Itoh F, Imai K et al. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin Biochem 2003; 36: 511-518.
34. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
35. Weiss AS, Sandmaier BM, Storer B, Storb R, McSweeney PA, Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6: 89-94.
36. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate. Dos and don'ts for assessing kidney function. Postgrad Med 2001; 110: 55-62; quiz 11.
37. Schwartz GJ, Brian LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34: 571-590.
38. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.